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HIV-2 contributes approximately a third to the prevalence of HIV in West Africa and is present in signiﬁcant amounts in
several low-income countries outside of West Africa with historical ties to Portugal. It complicates HIV diagnosis,requiring more
expensive and technically demanding testing algorithms. Natural polymorphisms and patterns in the development of resistance
to antiretrovirals are reviewed, along with their implications for antiretroviral therapy. Nonnucleoside reverse transcriptase
inhibitors, crucial in standard ﬁrst-line regimens for HIV-1 in many low-income settings, have no eﬀect on HIV-2. Nucleoside
analogues alone are not suﬃciently potent enough to achieve durable virologic control. Some protease inhibitors, in particular
thosewithoutritonavirboosting, are notsuﬃcientlyeﬀective againstHIV-2. Followingreview ofthe availableevidence andtaking
the structure and challenges of antiretroviral care in West Africa into consideration, the authors make recommendations and
highlight the needs of special populations.
1.Introduction
HIV-2 represents a distinct lineage of HIV, stemming from
SIVsm instead of the SIVcpz responsible for HIV-1. Like
HIV-1 it appears to have made the transition to humans
more than once, giving rise to eight distinct groups, of which
groups A and B account for nearly all of the cases identiﬁed
thus far [1]. HIV-2 diﬀers from HIV-1 most strikingly in its
lower rate of progression and infectivity, with the majority
of those infected likely to be long-term nonprogressors
[2–4]. Those with progressive disease experience the same
likelihoodof morbidity and mortality asare seen with HIV-1
[5, 6]. People with advanced HIV-2 infection require treat-
ment with antiretroviral therapy (ART), but most individual
antiretroviral drugs and regimens have been designed and
optimized for HIV-1 and cannot be assumed to provide
optimal viral suppression for HIV-2 infection. In some
instances, antiretroviral susceptibility diﬀers signiﬁcantly
between HIV-1 and HIV-2, such that HIV-2 is intrinsically
resistant to two of the major classes of antiretroviral drugs:
the fusion inhibitors and the nonnucleoside reverse tran-
scriptase inhibitor- (NNRTI-) based regimens that are the
standard therapy for HIV-1 in West Africa [7, 8].
The challenge of treating HIV-2 infection falls mainly
upon West Africa [6], with current prevalence estimates
ranging up to 1% where reported, compared with HIV-1
prevalence rates of up to 3.4%, therefore comprising a
substantial portion ofall HIVinfectionsin thesubregion [9].
The exception to this is Guinea-Bissau, where the prevalence
amongst adults was estimated to be 8%–10% two decades
ago [10]. This has now changed to a current prevalence
of around 4%, compared to an HIV-1 prevalence of 2.9%
in rural areas and 4.2% in urban areas [11–13]. European
countries with colonial links to West Africa such as Portugal,
France, and the United Kingdom, as well as other countries
with prior Portuguese ties, such as Angola, Brazil, India, and
Mozambique, also have sizeable cohorts of HIV-2 infected
individuals [14–18]. Although the absolute numbers of
patients infected with HIV-2 in European cohorts are small,
the earlier availabilityofART in these countrieshas provided2 AIDS Research and Treatment
some data to guide treatment recommendations in resource-
poor settings.
Given the prevalence of HIV-2 in West Africa, it is
imperative that up-to-date recommendations be available
for the antiretroviral management of HIV-2 in these clinical
settings, characterized by the use of standardized ﬁrst-,
and in some cases second-line regimens based on limited
formularies, with treatment decisions driven by protocol,
that are also highly sensitive to cost. At the time of writing,
therapeutic drug monitoring, viral load measurement, and
genotypic resistance testing are not routinely available in
West Africa, nor are coreceptor tropism assays or HLA
typing (to guide the safe use of CCR5 receptor blockers or
abacavir, resp.). The monitoring and care of HIV in sub-
SaharanAfricahas,however,beenalitanyofbarriersbrought
down, and the “impossible” becomes the standard, so these
recommendations seek to strike a balance between optimal
and current management trends.
Clinical trials of ART in HIV-2 are few compared with
HIV-1, primarily because of HIV-2’s lower prevalence and
virulence, not to mention its concentration among some of
the world’s poorest people. Until there is better evidence
from randomized controlled trials, judgment of what consti-
tutes good care in HIV-2 management must therefore rely on
both in vitro as well as in vivo data from small cohort studies
andcaseseries,theoreticalassertions, andparallelswithHIV-
1 therapeutics.
As will be apparent to experienced clinicians and pro-
gram oﬃcers, numerous potential factors have been left out
of this work that might inﬂuence program-level decisions
about ART for HIV-2 in West Africa. This is especially true
where such factors aﬀect both HIV-1 and HIV-2 infections
in the same way. The current work is not intended as an
exhaustive review of all aspects of a public health approach
to the use of ART, nor is it intended to function as an
ART primer. However, in the absence of universally accepted
treatment guidelines for HIV-2, the authors seek to provide
their own recommendations, based on the available litera-
ture, HIV-2 treatment meetings, discussions with colleagues
from major HIV-2 treatment centers in Europe and Africa,
and from personal experiences between 2003–2010 at the
Genito-Urinary Medicine clinic at the MRC Laboratories in
The Gambia, where ART was provided to HIV-2 infected
people.
2.SelectingFirst- andSecond-LineART
Regimes in HIV-2
2.1. Natural Polymorphisms and Patterns of Genotypic Resis-
tance in HIV-2. The most crucial diﬀerence between HIV-1
andHIV-2when consideringsuitableARTregimesisthelack
of susceptibility of the latter to what would now be called
ﬁrst-generation NNRTIs, nevirapine, and efavirenz [19, 20].
The natural resistance of HIV-2 to these drugs is due to
diﬀerencesin theamino acidresiduesthat makecontactwith
the NNRTI in the binding pocket of HIV-1 and HIV-2, par-
ticularly the Y181I and Y188L natural polymorphisms seen
in HIV-2, which signiﬁcantly reduce NNRTI binding [7].
It is worth noting that HIV-1 mutations at these positions
result in complete resistance to NNRTIs [20, 21]. Although
etravirine is reported to have more activity against HIV-2
than previous NNRTIs, the presence of L181 and other
structural diﬀerences in the HIV-2 NNRTI-pocket makes
HIV-2 naturally resistant to etravirine as well (reviewed in
[22, 23]).
Nucleos(t)ide reverse transcriptase inhibitors (NRTIs)
have a similar potency in both HIV-1 and HIV-2. Earlier
in vitro work demonstrating lower potency for zidovudine
(AZT) [24] appeared to be an artifact of the assay used,
and more recent work demonstrates similar potency in both
HIV-2 and HIV-1 [25]. The development of NRTI resistance
in HIV-2 shares many parallels with that in HIV-1, although
key diﬀerences are worth highlighting that are of clinical
relevance. The M184V mutationoccurs rapidly, both in vitro
[26]an din vivo[27]inapproximately83%ofpatientsfailing
a lamivudine (3TC)-containing regimen [28, 29]. As in
HIV-1, it is associated with high-level phenotypic resistance
to 3TC and emtricitabine (FTC) in HIV-2-infected individu-
als[30].AlthoughHIV-1and HIV-2share some classic NRTI
resistance patterns, the preference for alternative resistance
pathways has been noted, in addition to unique resistance
patterns in HIV-2. AZT resistance in HIV-1 occurs via
two well-documented pathways. The most common and
preferred pathway is marked by the accumulation of the
six thymidine-associated mutations (TAMs): M41L, D67N,
K70R, L210W, T215Y, and K219Q/E [31]. The less common
pathway is via the Q151M mutation, which also tends to
develop later. The TAM mutationsa r ec o n s p i c u o u s l ya b s e n t
in the AZT resistance proﬁles of HIV-2 patients [27, 28,
32–35]. In place of TAMs, AZT resistance in HIV-2 often
involvestheQ151Mmutation,which occursfasterandwitha
much higher frequency and potency than in HIV-1 [30, 36].
Considering thatthis mutationcauses multi-NRTIresistance
in HIV-2, its high frequency raises real concerns [29, 37].
Unlike HIV-1 where K65R leads to TDF, ABC, ddI, and d4T
resistance [38], K65R in HIV-2 does not cause phenotypic
resistance toTDF,butcauseshigh-levelresistanceto3TCand
FTC, and low-level resistance to ddI [30]. Current evidence
suggests that this mutation rarely occurs in HIV-2 except
during suboptimal mono- or dual-therapy with NRTIs that
mostly do not include TDF [27, 39, 40], where it is often
associated with the Q151M mutation. There is, however,
limited experience with widespread use of TDF containing
regimes in ﬁrst-line HIV-2 ART, and ﬁrm conclusions on
a reduced frequency of K65R in HIV-2 infection cannot
be drawn with conﬁdence. Of note, in a recent Senegalese
study, two (of 23) patients exhibited K65R mutations at
follow-up while on an AZT/3TC/indinavir (IDV) regimen,
although in one case the mutation was present at baseline
prior to commencing ART [35]. These data together with
the phenotypic data by Smith et al. [30] indicate that K65R
arises primarily due to 3TC/FTC pressure in HIV-2. The
potential fragility of currently available NRTI backbones for
use in HIV-2 therapy is highlighted by the ﬁnding that
Q151M combined with K65R or M184V results in high-
level AZT and 3TC resistance, whereas the presence of all
three mutations in combination confers class-wide NRTI
resistance, although it should be noted that these mutationsAIDS Research and Treatment 3
result only in low level resistance (4-5 fold) to d4T and
TDF [30]. Lastly, the L74V mutation is rarely documented
in HIV-2 [41], with one report of L74I in an HIV-2-infected
patient on dual therapy (which included ddI) [40].
HIV-1 and HIV-2 proteases havean amino acid sequence
similarity of about 50%, substantially less than that observed
intheir reversetranscriptase enzymes. These sequencediﬀer-
ences are reﬂected in very distinct natural polymorphisms in
the HIV-1 and HIV-2 proteases, most of which occur outside
the functionally relevant areas [42]. Several HIV-2 natural
polymorphisms correspond to drug resistance mutations in
HIV-1. These include the major drug resistance mutation
M46I, conferring resistance to indinavir (IDV), and several
minor mutations, L10V, V32I, M36I, I47V, A71V, and G73A,
that may decrease the activity of nelﬁnavir (NFV) and
amprenavir (APV) [32, 43–46]. Several in vitro cultural and
cell-free assays using individual PIs have suggested that while
IDV, saquinavir (SQV), lopinavir (LPV), darunavir (DRV),
andtipranavir(TPV)mayexertfullactivityagainstwild-type
HIV-2 [47–52], NFV and APV show a signiﬁcant reduction
inactivity[46,53].Amorein-depthstudy(kineticinhibition
a s s a y s )h a ss h o w nt h a tL P V ,S Q V ,T P V ,a n dD R Ve x h i b i t
the highest potency in this order and that atazanavir (ATV),
NFV, and APV show the lowest potency, respectively [54].
The data on TPV are however controversial, with other
studies showing several fold lower potency when compared
to LPV, SQV, and DRV [55, 56]. Once protease inhibitor-
(PI-) based ART starts, this background of minor mutations
may result in rapid acquisition of a multi-PI resistance
phenotype [45, 46].
In HIV-1, PI resistance is associated with the accu-
mulation of four or more resistance mutations in the
protease gene,though major mutationscan cause substantial
resistance on their own [57]. HIV-1 and HIV-2 have similar
PI resistance mutations [33, 43, 45, 46, 53], with a few muta-
tions unique to HIV-2 [20, 45, 46]. The presence of certain
natural polymorphisms in HIV-2 can reduce the time to
resistanceinsomecases [34,46].Forinstance,I47AandV32I
are associated with high-level resistance to LPV/ritonavir
(LPV/r) in HIV-1 [58–60], and V47A is associated with
phenotypic resistance to LPV/r in HIV-2 [61]. In HIV-1, the
emergence of the LPV/r mutation I47A is a two-step process
(I → V → A), whereas in HIV-2 it can occur in a single step
from V → A[ 61]. In addition, V321 is present naturally in
HIV-2. Therefore while LPV/r resistance in HIV-1 requires
the acquisition of V32I and a two-step process to acquire
I47A, only a one-step change in HIV-2 is required, making
the development of this mutation easier and faster in HIV-2
[34].
2.2. Potential Options for Standardized First- and Second-
Line Regimes in Resource Poor Settings. Until recently, most
studies reporting antiretroviral use in HIV-2 patients were
from European cohorts, and often involved mono- or dual-
therapyand multipleheterogeneousregimens [28,32,33,40,
62]. Due to the recent availability of ART in West Africa,
data from the use of standardized ﬁrst-line ART regimens
in these cohorts are now appearing [34, 35, 63], although
the numbers are still relatively small when compared to
the HIV-1 literature. Given the lack of utility of NNRTIs
in HIV-2, a key issue in choosing ﬁrst-line ART regimes
in HIV-2 infection is the question of whether triple NRTI
regimens areaviable,safe,andeﬃcaciousoption.Theappeal
of this approach lies in its lower pill burdens and reservation
of PIs for second-line therapy, maintaining parallels with
HIV-1 protocols. Prior to the development of a heat stable
formulation of ritonavir, and in settings where this is not
yet available, cold chain requirements also argue for a PI-
sparing regimen. Unfortunately studies to date suggest that
these regimes, including those with TDF, perform poorly in
HIV-2 [28, 62, 64] and in our opinion should be avoided,
althoughincertainspeciﬁccircumstancestheymayrepresent
the best balance of risk and beneﬁt (see special populations,
below). One case of a patient achieving viral suppression on
a quadruple NRTI regimen (d4T/3TC/ABC/TDF) has been
reported [62], although clearly more evidence is needed to
conclude that such a regimen is superior to using triple
NRTIs in HIV-2. The principal challenge of the PI-sparing
nucleoside regimens in HIV-2 is the rapid development of
the Q151M pan-NRTI resistance mutation [36]. Unlike the
case in HIV-1 where this typically arises only after multiple
other resistance mutations have developed, in HIV-2 it is
one of the earliest and most common NRTI mutations
(after those at the M184 locus), especially after mono-/dual-
/triple-NRTI treatment [28, 32, 33, 40, 62] and compromises
theentir er egimen[36].Triplenucleotideregimescontaining
ABC(intheabsenceofTDF)havealsobeenshowntorapidly
select for K65R in HIV-2 patients [64].
Our experience at the MRC Gambia [34]a n dt h a to f
others [62, 65] suggest that the combination regimen of
AZT/3TC and LPV/r has a reasonable chance of success
as a ﬁrst-line regime for HIV-2 infection [34, 62, 65].
The use of an AZT/3TC backbone with unboosted IDV,
however, has been shown to result in a high proportion
of ART failures and accumulation of resistance mutations
in a Senegalese cohort [35, 56]. ABC/3TC, TDF/FTC, and
ddI-based regimens have the advantage of daily dosing and
show potential for success, although in our opinion there
is currently insuﬃcient experience with those combinations
in HIV-2 to draw ﬁrm conclusions. Moreover the inclusion
of appropriate PIs in HIV-2 regimes will necessitate twice
daily dosing in most circumstances, reducing the beneﬁt
of once-daily nucleoside analogue dosing. Didanosine also
has a rather unique set of advantages and disadvantages as
part of ART regimes. It should generally be taken on an
emptystomachwhileotherantiretrovirals, inparticularTDF,
should be taken with food, adding to regimen complexity.
We believe ddI is less well tolerated than ABC, AZT, TDF,
or 3TC and that this could threaten patient adherence to the
overallregimen.ItsusewithTDFisrelativelycontraindicated
because of the negative impact this combination has on
CD4 cell counts and the increased risk of viral failure
[66], even at the appropriate 250mgdose [64]. Although
no head-to-head comparisons have been performed in
HIV-2-infected individuals, the HIV-1 literature suggests
that an NRTI backbone of TDF/FTC (or 3TC) may, on
the grounds of eﬃcacy and tolerability, be a better choice
than AZT/3TC [67, 68]o rA B C / 3 T C[ 69, 70]. On that4 AIDS Research and Treatment
basis, TDF may be desirable in ﬁrst-line treatment in spite
of its greater cost when compared with AZT (see Table 2),
although the low yet measurable risk of renal toxicity with
TDFuse,particularly insettingswhererenal monitoringmay
be limited, is grounds for concern [71]. Tolerability issues
should also be considered. If a patient does not tolerate
AZTinﬁrst-linetreatmentotheralternatives(includingd4T)
could be used, following the same protocols as are used
for AZT intolerance in HIV-1-infected individuals; however
an equivalent substitute for TDF in the face of resistant
virus is not easy to ﬁnd in the event of TDF intolerance.
Given that the prevalence of HLA B∗5701 is low in black
African individuals [72], with HLA∗B5703 being the only
B57subtypefoundinpopulationsinGuinea-Bissau [73],the
risk of ABC hypersensitivity, if ABC/3TC is used ﬁrst line
without the ability to determine HLA type, may not be of
great concern in sub-Saharan Africa.
As mentioned above, PI options are constrained in
HIV-2 as a result of natural polymorphisms that support
PI resistance. In addition, unboosted PI regimens should
be avoided as they tend to perform poorly [29, 35, 40, 56].
WhilegoodclinicaloutcomeswithLPV/rhavebeenobserved
[34, 65], in vitro data [54] suggests that SQV/r would be a
reasonable ﬁrst-line PI [54] too, while IDV/r may also be
eﬀective [28]. DRV/r would appear to be reliable based on
in vitro data, although at present there is insuﬃcient data
to justify its use as the preferred ﬁrst-line PI for HIV-2
given its higher cost (see below). Boosted ATV cannot be
recommended in HIV-2 [54, 55], and given the conﬂicting
results on the use of boosted TPV [54–56], it also cannot
be recommended for use until further studies conﬁrm its
eﬃcacy.
Second-line therapy should be considered in drafting
treatment guidelines for ﬁrst-line ART, as initial regimen
choices narrow later treatment options. In the absence of
viral load monitoring, resistance should be anticipated at
the time of regimen change, and we make the assumption
that resistance test results will not generally be available.
Two fundamentally diﬀerentstrategies in ARTare toincrease
potency up-front in order to minimize failure rates, or to
hold potent antiretrovirals in reserve in order to mitigate
the impact of failure of the ﬁrst-line. Knowledge of typical
mutations selected for during failure allows one to optimize
sequential treatment, although HIV-2 is much less well
studied in terms of the frequency with which various
sequential regimens select for resistance mutations.
With regards to NRTIs, extensive resistance should be
assumed to include the Q151M, K65R, and M184V, depend-
ing on the NRTIs employed in the ﬁrst-line ART. While ABC
is probably an option where only the Q151M mutation is
present, it would be compromised in the presence of K65R
and M184V [30]. Older NRTIs including AZT and ddI are
not likely to have much residual potency in the face of these
mutations; however TDF and d4T might retain suﬃcient
potency in this setting [30]. The argument that the M184V
mutation carries a substantial ﬁtness cost has not been
demonstrated as clearly in HIV-2 as it has in HIV-1 [75],
nonetheless asitoccursinthehighlyconservedYMDD motif
within the reverse transcriptase’s active site [76], we believe
it is likely to aﬀect ﬁtness similarly, and we recommend
continued exposure to 3TC or FTC in order to maintain the
M184V.
Based on the resistance data described earlier, recom-
mended ﬁrst-line boosted PIs for HIV-2 in resource limited
settings are LPV/r, SQV/r, and possibly IDV/r. It appears
that HIV-2 V47A mutants, selected for by failure on a LPV/r
regimen, retain susceptibility to other PIs and are in fact
hypersusceptible to ATV and SQV [61]. We ﬁnd that this
makes SQV/r an attractive choice for second-line therapy to
follow up LPV/r-based ART in HIV-2.
Given the more limited range of eﬀective antiretrovi-
rals, both biologically and as a consequence of HIV-2’s
disproportionate prevalence in the resource-limited settings
of West Africa, second-line treatment in HIV-2 becomes
markedly challenging. Going back to the broader question
of strategy, we support a boosted PI in the ﬁrst regimen
b e c a u s ew eb e l i e v et h a tf a i l u r er a t e so nt r i p l eN R T Ir e g i m e n s
are unacceptable. Nonetheless we recommend TDF be held
in reserve to lend potency to second-line treatment.
2.3. HIV-1/HIV-2 Dual Infection. Co-infection with both
HIV-1 and HIV-2 occurs in countries where both viruses
circulate. Although progression, as implicated by higher
viral loads, is driven by HIV-1 in the majority of dually
infected individuals [77], this is not always the case [34].
Treatment of dually infected individuals should be carried
out using an HIV-2 regimen, to ensure that the drugs used
can eﬀectively treat both viruses [34, 78]. Given that the
HIV-2 plasma viral load is usually undetectable or low
in dual infections, it might seem reasonable to treat and
monitor only HIV-1 (discussed in [79]). In our opinion this
represents a dangerous strategy, as evenwith an undetectable
baseline HIV-2 VL, the risk exists that as HIV-1 is controlled
and CD4+ T-cell targets expand, the potential for HIV-
2 replication will also increase [78]. In addition, we have
successfully treated eight dually infected individuals on
an HIV-2 regimen of AZT/3TC/LPV/r achieving complete
suppression of both viruses for more than three years [34].
Taken together, Tables I(a) and I(b) show possible com-
binations that would be likely to optimize control of HIV-2
in mono- and dual-infections, across two regimens, with the
authors’ preference given in bold.
2.4. Other Agents. While some newer agents developed for
use against HIV-1 show no activity against HIV-2 and
other products are currently unrealistic options in resource
poor settings, they warrant discussion even if they lie far
outside the protocols and budgets of West African treatment
programs currently. With potentially increasing numbers of
HIV-2 infected patients with ﬁrst-line (and perhaps second-
line) regimen failures in West Africa, increasing experience
with the use of newer agents in salvage therapy in European
settings and, hopefully, the costs of newer agents dropping
over time, HIV-2 ART guidelines will require frequent
reconsideration and updates.
Two types of entry inhibitors, fusion inhibitors (FI)
and coreceptor binding inhibitors, have been approved forAIDS Research and Treatment 5
Table 1
(a) Potential ﬁrst- and second-line NRTI backbones for HIV-2 and dual
infection
First-line Second-line
AZT/3TC TDF/AZT/3TCor FTC
TDF/FTC or 3TC∗ TDF/AZT/3TC or FTC
ABC/3TC TDF/AZT/3TC or FTC
∗FTCand3TCareassumedtobeessentiallyequivalentinthetable,despite
FTC’s possible superiority and 3TC’s possibly lower cost.
(b) Potential ﬁrst- and second-line PIs for HIV-2 and dual infection
First-line Second-line
LPV/r SQV/r or DRV/r
SQV/r LPV/r or DRV/r
IDV/r LPV/r or SQV/r or DRV/r
Table 2: Representative daily costs of selected antiretrovirals in
West Africa in 2010 [74]. All values represent amounts paid since
01/01/2010 in West Africa except where otherwise noted, in which
case the nearest equivalent in terms of year of purchase and income
was used.
Drug Cost per daya
AZT/3TC $0.28–$0.36
d4T/3TC $0.12
ABC/3TC $1.38b
ddI (400mg buﬀered) $0.79
3TC $0.08–$0.10
TDF $0.72c
TDF/FTC $0.87–$0.88c
LPV/r $1.24–$1.56d
IDV $0.96d
SQV $7.20e
DRV $22.12–$28.40f
Ritonavir (100mgbd) $0.22–$0.96d
aC o s t sa r eg i v e ni nU Sd o l l a r sf o rs t a n d a r dd o s e sg i v e nt w i c ed a i l yo rd a i l y
i nt h ec a s eo fT D F ,d d I ,A B C / 3 T C ,a n dT D F / F T C
bDominican Republic; 2008
cRepublic of South Africa, Somalia
d2009
eEgypt
fBulgaria, Jamaica;2009.
HIV therapy. Enfurvitide (T20), a fusion inhibitor currently
licensed for use in HIV-1, has been found to have no
activity against HIV-2 [8] which is not surprising given
that HIV-1 and HIV-2 only share an amino acid sequence
similarity of less than 30%–40% in the Env protein [80].
Maraviroc,a coreceptorbindinginhibitor, works by blocking
the CCR5 receptor, thereby inhibiting the virus from further
conformational changes that will allow fusion with the
host membrane. The activity of maraviroc against HIV-2
has not been formally tested, but since this drug binds to
the CCR5 receptor, it should work against R5-tropic HIV-
2v i r u s e s[ 81, 82]. A recent case report demonstrates the
inclusion of maraviroc in a regime used successfully to
control resistant HIV-2 infection [83]. However, the ability
of HIV-2 eﬃciently to utilize other coreceptors may limit
the eﬀectiveness of these antagonists in HIV-2 treatment
[84]. Another potential concern is the switch or emergence
of X4-tropic viruses, which is associated with faster disease
progression [84]. Although R5 to X4 switch has only
been reported in a few HIV-2-infected individuals [85], a
limited number of X4-tropic viruses have been isolated from
symptomatic patients [80].
Integrase inhibitors (INIs) work by interfering with
the insertion of HIV DNA into host DNA and raltegravir
(RAL), the ﬁrst licensed INI for HIV-1 therapy, appears to
be safe and eﬃcacious in both ART na¨ ıve [86]a n dA R T -
experienced patients [87]. Despite the 40% heterogeneity in
HIV-1andHIV-2integrasegenes,thefunctionallyimportant
motifs (the catalytic triad DDE, the HHCC, and RKK) are
100% conserved in HIV-1 and HIV-2 [88, 89]. In vitro
susceptibility of 14 clinical HIV-2 isolates, as well as HIV-2
ROD, to RAL, has showed similar activity for HIV-1 and
HIV-2 [88]. In vivo studies on highly treatment-experienced
HIV-2-infected individuals, two with group A [88, 90]a n d
one with group B [91], showed promising results, with
viral loads reduced to undetectable results, when RAL was
used in combination therapy. HIV-2 resistance to RAL in
vivo occurs via the N155H mutation [91]w h i c hi sa l s o
associated with phenotypic resistance against RAL in HIV-2
[92].However, these HIV-2 N155Hmutants, likethe M184V
mutation in the reverse transcriptase, are much less ﬁt than
t h ew i l dt y p e[ 75, 92]. This loss in replicative capacity can
be exploited when viral suppression is no longer a realistic
goal of therapy, and maintaining these mutations through
continued selective pressure can slow disease progression.
3.SpecialCircumstances
3.1. Pregnancy. While the risk of HIV-2 transmission in
pregnancy only reaches about 4% (including breast milk
transmission) [93], clinical and in vitro data would suggest
that AZT monotherapy as part of a prevention of mother
to child transmission program poses a considerable threat
to the mother, and to the child in the event of infection,
of selecting for the Q151M mutation with subsequent pan-
NRTI resistance [36]. Boosted PI-based ART through the
latter two trimesters of pregnancy and the breastfeeding
period should be the mainstay of vertical transmission
prevention;howeverboosted PIsmayresultingreaternausea
or insulin resistance in a small number of patients [94].
Dosing of PIs in pregnancy is not well validated, with
evidence of reduced plasma concentrations with several
agents, especially when used unboosted [95, 96]. Recent
ﬁndings suggest that in the absence of TDM, LPV/r dose
should be increased 50% in the second and third trimesters
of pregnancy [97]. SQV/r is probably eﬀective at its standard
dose of 1000/100mg twice daily [98, 99]a n dI D V / ra ti t s
standard dose of 800/100mg twice daily may be adequate,
but further clariﬁcation is required [100]. As with HIV-1,
concerns exist about the use of TDF as part of the nucle-
oside backbone during pregnancy potentially interfering6 AIDS Research and Treatment
with bone mineralization, although it has not as yet been
associated with congenital abnormalities [101].
3.2. Tuberculosis (TB) Coinfection. TB is endemic in West
Africa, and the problematic drug interactions between
PIs and rifampin are well known, with induction of the
cytochrome P450 system by rifampin resulting in accelerated
metabolism of PIs, making eﬀective dosing of the PIs more
diﬃcult to achieve. Provision of rifabutin as part of TB
therapy for HIV-2 co-infected patients would therefore be
ideal, allowing for the more predictable pharmacokinetic
interactions betweenLPV/r andrifabutin.HoweverTBtreat-
ment protocols, particularly where TB and HIV treatments
are managed by diﬀerent health care providers, might not
adopt rifabutin as a result of cost or other considerations.
In this case, where ART cannot be safely deferred, a PI-
sparing regimen may represent the best balance of safety and
eﬃcacy for HIV-2/TB co-infected patients. Increasing the PI
dose, for example doubling the dose of LPV/r, may be an
alternative, although achieving therapeutic drug levels with
tolerable dosing of LPV/r appears challenging [102, 103]. If
a triple or quadruple NRTI regime is used, ART should be
reassessed once TB treatment is completed and the patient
switched to a boosted-PI regimen.
3.3. Chronic Hepatitis B (HBV) Co-Infection. Chronic HBV
infection is common in West Africa, with prevalence rates
of 8%–20% [104–106]; as a consequence many individuals
infectedwithHIV-2canbeexpectedtohavechronicHBVco-
infection and a substantial proportion is likely to have high
HBVviremia. Unlikethe epidemiologyin Western countries,
most HBV transmission occurs between children and is
not due to shared risk factors for transmission as between
sexually active or intravenous drug using adults [107].
Screening protocols for comorbidities in HIV care settings
in HBV endemic countries should include HBsAg, either for
all new patients or at a minimum for those with evidence
of liver disease, such as transaminitis. Where chronic HBV
is present, ideally TDF/FTC or TDF/3TC should be in the
ﬁrst-line ARTregimen [108],althoughthisrecommendation
may be diﬃcult tofollow where HBVdiagnostics are limited.
Moreover it introduces another layer of complexity into
protocol-based sequential ART. Clearly these issues would
be addressed if TDF/FTC (or 3TC) were adopted as the
preferred NRTI backbone, although it may be necessary to
maintain them in succeeding regimens, regardless of the
addition of other agents, to avoid the risk of HBV “ﬂare”
arising with their discontinuation [109].
3.4. Childhood. Childrenwith HIV-2 infectionpresent many
of the same challenges as those with HIV-1 infection, such
as concerns about dosing, formulations, and speciﬁcally
TDF toxicity [110]. The principal diﬀerences, that vertical
HIV-2 transmission is distinctly less common and that it
is not rare for perinatal HIV-2 infections to present in
teenagers, do not argue for any speciﬁc diﬀerences in their
management compared to children with HIV-1, beyond
their antiretroviral regimen being appropriate for HIV-2 as
described above for adults.
4.OperationalIssues
Endemic HIV-2 brings with it complications in terms of
program management in West Africa beyond the necessary
alterations intheantiretroviral therapy protocols,speciﬁcally
that it complicates HIV testing and management of both
stocks and staﬀ.
4.1. Diagnosis. Testing to distinguish HIV-1 from HIV-2 and
dual infection can be complicated and expensive due to the
presence of cross-reactive antibodies and strain diﬀerences
[111, 112]. Screening tests need high sensitivity for HIV-
2, while conﬁrmatory testing may require multiple steps in
order to reliably distinguish between HIV-1, HIV-2, and
HIV-1/HIV-2 dual infection, detailed review of which is
beyond the scope of this paper. The alternative to these more
demanding and elaborate testing protocols is misdiagnosis,
primarily over-diagnosis of HIV-1/HIV-2 dual infection,
resulting in HIV-1 monoinfected people going onto more
expensive and cumbersome PI regimens. Diagnostic clarity
therefore is a trade-oﬀ between higher upfront costs in
testing and savings over the longer term in pharmaceuticals,
although no rigorous analysis of costs has yet been made in
this context. Misdiagnosis that results in HIV-2 and dually
infected patientsgoingontreatment thatignorestheir HIV-2
carries a greater risk, as discussed earlier.
4.2. When to Start. Compared with HIV-1, more patients
with HIV-2 will be long-term nonprogressors or slow
progressors. Although this could be used to argue for a later
CD4-driven initiation of ART, it has been demonstrated that
immunological recovery on ART is worse in HIV-2 com-
pared with HIV-1 [113] and excessive delay in initiating ART
may carry long-term negative immunological consequences.
While the authors support initiating treatment for HIV-2
below a CD4 count of 350/mm3 or possibly higher, instead
ofbelow200/mm3,it may beoperationally awkward toapply
diﬀerent CD4 cut-oﬀs for starting ART in HIV-1 and HIV-2
where CD4-driveninitiation of therapy has not yet advanced
to the earlier thresholds.
4.3. Monitoring. There is little evidence to suggest that
monitoring of patients on ART should be any diﬀerent
for HIV-2 than for HIV-1. In practice the lack of a
commerciallyavailableviralloadassay[114]makesviralload
measurements harder to obtain for HIV-2. CD4 recovery has
beenfound to be bluntedinHIV-2 [113]; combinedwith the
more limited treatment optionsforHIV-2thisargues against
considering a lack of substantial CD4 gains on ART to be a
failure. Other immunologic criteria, including a drop from
peak or a return to baseline CD4, may not be any worse for
monitoring response to treatment in HIV-2 than in HIV-1.
4.4. Stock Management. In terms of stock management,
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will be to avoid stock shortages and wastages. Endemic
HIV-2 complicates the program. The numbers of HIV-2
patients needing ART are harder to estimate and may vary
with changes in testing algorithms (see Section 4.1). As
HIV-2 patients on ART will represent a small minority of
a program or project’s total number of HIV patients, small
ﬂuctuations in their number result in disproportionately
large ﬂuctuations in utilization rate, a situation that is
further exacerbated for second-line treatment and pediatric
cohorts. Stock management for pediatric cohorts with their
heterogeneity in terms of weight, physical maturity, and
ability to swallow pills is particularly diﬃcult, and pediatric
HIV-2 cohorts are likely to be extremely small. Partial
standardization across both HIV-1 and HIV-2 regimens, for
e x a m p l eu s i n gt h es a m eN R T I sr e g a r d l e s so fH I Vt y p eo r
using the same PI for HIV-2 ﬁrst-line treatment that one
uses for HIV-1 second-line treatment, may simplify stock
management and reduce shortages and wastage.
Another factor aﬀecting ART choices in West Africa is
cost. While costs can be expected to vary over time and
between countries or regions, representative daily costs for
several combinations, primarily from West Africa in 2010,
are given in Table 2, although neither the costs nor the
ratios of costs that follow should be presumed to be static.
Compared with AZT, TDF and ddI are 2-3 times and ABC
4-5 times as expensive, while d4T costs half to one-third
as much. The most expensive part of the regimen is the
boostedPI,andthisisalsothemainsourceofcostdiﬀerences
between regimens. Compared to coformulatedLPV/r, SQV/r
is 5–7 times and DRV/r 14–23 times as expensive, while
IDV/r is approximately of the same cost. Comparisons of
costs should also take eﬃcacy into account. Depending on
themodeland assumptionsthismayresultinmedicineswith
a higher daily cost being more cost-eﬀective, as has been
recently shown for TDF in ﬁrst-line ART in India [115].
4.5. Training and Protocol Development. The diﬀerences in
recommendations between HIV-1 and HIV-2 and the dosing
complications, particularly with TB cotreatment and in late
pregnancy, pose further challenges to front line staﬀ involved
in program implementation in the HIV-2 endemic areas
of West Africa. More complicated protocols call for more
detailed training of staﬀ. Greater diagnostic ambiguity and
a broader range of ART regimens require more complete
medical records. Finally patients getting information from
various sources, especially long-term nonprogressors, need
additional counseling to understand their disease.
5.SummaryRecommendations
West African and other programs faced with HIV-2 patients
need locally adapted protocols for testing, treatment, moni-
toring, and stock management in order to be eﬀective.
With regards to treatment, the delivery of optimal therapy
should be a program goal, and although more complicated,
it is achievable within a public health framework, with
nurse-led clinics, even where infrastructural or staﬃng
deﬁcits may exist. For adults with HIV-2 or HIV-1/HIV-2
dual infection without access to ART susceptibility testing,
optimal antiretroviral therapies for ﬁrst- and second-line
treatment are suggested in Tables I(a) and I(b).I ti sh o p e d
that these recommendations will rapidly become obsolete as
o t h e ra g e n t sa n dd r u gc l a s s e sc o m ei n t ow i d e ru s ei nW e s t
Africa, and prospective randomized controlled trials of ART
in HIV-2 provide more reliable indications of the suitability
of speciﬁc regimens.
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